Figure 4.
Cumulative incidence curves depicting the probability of progression into AML of patients with primary MDSs, without induction chemotherapy or stem cell transplantation, stratified by the absolute monocyte count (<0.2 × 109/L (n = 529), 0.2–0.4 × 109/L (n = 241), and >0.4 × 109/L (n = 223)) and “death without progression” as the competing event.
